Back to top

Analyst Blog

ARIAD Pharmaceuticals, Inc.’s (ARIA - Snapshot Report) share price was up 2.37% after the company announced that Iclusig was once again available in the U.S.

We remind investors that the marketing and commercial distribution of Iclusig in the U.S. was temporarily suspended in Oct 2013 following instructions from the FDA due to a higher-than-expected incidence of blood clots and narrowing of blood vessels.

The product now carries a revised label (indication) as well as a boxed warning along with updated safety information and recommendations regarding dosing. The label indicates that Iclusig is approved for the treatment of T315I-positive chronic myeloid leukemia (chronic phase, accelerated phase, or blast phase) or T315I-positive Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia, or chronic phase, accelerated phase, or blast phase chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia in patients for whom no other tyrosine-kinase inhibitor therapy is indicated.

Meanwhile, the starting dose remains unchanged at 45mg daily.

The resumption of marketing of Iclusig in the U.S. is a positive development for ARIAD. ARIAD’s shares have been on a rollercoaster ride ever since news regarding safety issues surrounding Iclusig first emerged. Now that Iclusig is back in the market, we expect investor focus to remain on the product’s performance. Iclusig sales for the quarter ended Sep 30, 2013 were $16.7 million.

ARIAD carries a Zacks Rank #2 (Buy). Other players which look attractive at current levels include Endocyte, Inc. (ECYT - Snapshot Report), Grifols, S.A. (GRFS - Snapshot Report) and Biodel Inc. (BIOD - Snapshot Report). While Endocyte and Grifols are Zacks Rank #1 (Strong Buy) stocks, Biodel is a Zacks Rank #2 stock.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UNITED THER… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%